Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence By Ogkologos - November 5, 2025 150 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 238 Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Heartburn Medications Pulled From Shelves Because They May Cause Cancer January 13, 2020 2026 ESMO Breast Cancer Award Recipient Announced March 31, 2026 Antitumour Activity of Combination of Lenvatinib and Pembrolizumab in Patients with... August 2, 2022 Nivolumab Plus Ipilimumab Demonstrates Long-Term Survival Benefit in Patients with Advanced... May 28, 2024 Load more HOT NEWS Drinking Alcohol, Often Heavily, Common among People with Cancer and Long-Term... Zero Mutation ctDNA Triage for Selection of Patients with Metastatic Colorectal... We’re asking scientists to tackle 9 of the toughest challenges in... Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative...
